Fiche centre
Research Site
Kassel — Germany
Essais liés5clinical trials
VilleKassellocalisation
PaysGermanylocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT00252863
Essais cliniques associés
5| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Symbicort, used twice daily (b.i.d) and as needed (prn) | SEP | Phase 3 | NCT00252863 | DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults | COMPLETED |
| VIOLET — NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care | Lupus | À vérifier | NCT07424261 | VIOLET — NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care | RECRUITING |
| Rilvegostomig | Cancer | Phase 3 | NCT06627647 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC | RECRUITING |
| Rilvegostomig | Cancer | Phase 3 | NCT06692738 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | RECRUITING |
| Trastuzumab deruxtecan | Parkinson | Phase 3 | NCT06989112 | DE-01 — DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer | RECRUITING |